AstraZeneca PLC (NASDAQ:AZN) Shares Sold by James Investment Research Inc.

James Investment Research Inc. trimmed its position in AstraZeneca PLC (NASDAQ:AZN) by 0.6% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 83,088 shares of the company’s stock after selling 528 shares during the period. James Investment Research Inc.’s holdings in AstraZeneca were worth $6,473,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the company. McClarren Financial Advisors Inc. grew its position in shares of AstraZeneca by 320.8% in the third quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock valued at $25,000 after purchasing an additional 247 shares during the period. GHP Investment Advisors Inc. purchased a new stake in AstraZeneca in the 2nd quarter valued at about $26,000. Pathway Financial Advisers LLC acquired a new position in shares of AstraZeneca during the 1st quarter valued at about $29,000. Hobbs Group Advisors LLC purchased a new position in shares of AstraZeneca during the 2nd quarter worth about $35,000. Finally, Versant Capital Management Inc boosted its position in shares of AstraZeneca by 1,614.8% in the second quarter. Versant Capital Management Inc now owns 463 shares of the company’s stock worth $36,000 after acquiring an additional 436 shares during the last quarter. 20.35% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages recently commented on AZN. TD Cowen upped their price target on shares of AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Deutsche Bank Aktiengesellschaft downgraded AstraZeneca from a “hold” rating to a “sell” rating in a report on Friday, September 13th. Finally, Erste Group Bank upgraded AstraZeneca from a “hold” rating to a “buy” rating in a report on Wednesday, September 11th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, AstraZeneca has a consensus rating of “Moderate Buy” and an average target price of $89.75.

AstraZeneca Stock Performance

AstraZeneca stock opened at $71.42 on Friday. The company has a current ratio of 0.89, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. The stock has a 50 day moving average of $79.17 and a 200-day moving average of $78.60. The stock has a market cap of $221.44 billion, a P/E ratio of 34.50, a price-to-earnings-growth ratio of 1.32 and a beta of 0.47. AstraZeneca PLC has a 52 week low of $60.47 and a 52 week high of $87.68.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.